<DOC>
	<DOCNO>NCT00278460</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine docetaxel , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . PURPOSE : This phase II trial study well give gemcitabine together docetaxel work treat patient recurrent stage III stage IV non-small cell lung cancer .</brief_summary>
	<brief_title>Gemcitabine Docetaxel Treating Patients With Recurrent Stage III Stage IV Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine response rate patient recurrent stage IIIB IV non-small cell lung cancer treat gemcitabine hydrochloride docetaxel . - Determine overall progression-free survival patient treat regimen . - Determine toxic effect regimen patient . Secondary - Determine duration response patient treat regimen . OUTLINE : Patients receive gemcitabine hydrochloride IV 30 minute follow docetaxel IV 30 minute day 1 8 . Treatment repeat every 21 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically survival . PROJECTED ACCRUAL : A total 51 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage IIIB IV nonsmall cell lung cancer , include follow type : Squamous cell carcinoma Adenocarcinoma , include bronchoalveolar cell adenocarcinoma Large cell anaplastic carcinoma , include giant clear cell carcinoma Histologic cytologic documentation recurrence require Measurable evaluable disease , define mass reproducibly measurable 2 perpendicular diameter physical examination image The following lesion consider measurable evaluable : Bone disease Pleural pericardial effusion Previously irradiate lesion , unless subsequent progression document CNS metastasis allow provided patient undergoes least 2 week radiotherapy prior study entry PATIENT CHARACTERISTICS : Not pregnant nursing Fertile patient must use effective contraception Negative pregnancy test CALGB performance status ≤ 1 Life expectancy ≥ 3 month Granulocyte count &gt; 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Creatinine ≤ 2 time normal Bilirubin normal SGOT and/or SGPT ≤ 2.5 time upper limit normal ( ULN ) AND alkaline phosphatase ≤ 1.5 time ULN OR Alkaline phosphatase 4 time ULN SGOT and/or SGPT normal Ejection fraction normal ECHO MUGA No history congestive heart failure No psychiatric illness would preclude study compliance No serious medical psychiatric illness would preclude give informed consent limit survival &lt; 3 month No active uncontrolled bacterial , fungal , viral infection No malignancy within past 5 year except curatively treat carcinoma situ cervix breast , basal cell squamous carcinoma skin , surgically resect nonrecurrent primary tumor treat adjuvant radiotherapy chemotherapy No preexist peripheral neuropathy ≥ grade 2 PRIOR CONCURRENT THERAPY : At least 2 week since prior major surgery recover acute effect At least 2 week since prior palliative radiotherapy recover acute toxic effect Any persistent toxicity ( e.g. , alopecia hyperpigmentation ) associate clinical morbidity allow No prior chemotherapy No concurrent cranial thoracic radiation therapy No concurrent cytotoxic hormonal therapy Concurrent palliative radiotherapy allow relief localize pain obstruction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>bronchoalveolar cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>squamous cell lung cancer</keyword>
</DOC>